{"content":"<li class=\"n-box-item date-title\" data-end=\"1488517199\" data-start=\"1488430800\" data-txt=\"Sunday, December 22, 2019\">Thursday, March  2, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3248388\" data-ts=\"1488499922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248388-sling-tv-to-start-offering-nbc-regional-sports-nets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sling TV to start offering NBC regional sports nets</a></h4><ul>   <li>Sling TV (<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> <font color='red'>-1.9%</font>) will begin streaming NBC (<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-0.4%</font>) <a href=\"http://www.multichannel.com/news/content/sling-tv-stream-nbc-s-regional-sports-nets/411282\" target=\"_blank\">Regional Sports Networks</a> in some markets.</li>    <li>Starting later this month, eligible Sling Blue customers will get access to NBC's CSN California, CSN Bay Area, CSN Chicago and CSN Mid-Atlantic.</li>    <li>That will add baseball games to those that Sling customers can already get through national feeds and other regional sports nets from Fox and YES Network, in time for the sport's Opening Day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248388\" data-linked=\"Sling TV to start offering NBC regional sports nets\" data-tweet=\"$DISH $DISH $CMCSA - Sling TV to start offering NBC regional sports nets https://seekingalpha.com/news/3248388-sling-tv-to-start-offering-nbc-regional-sports-nets?source=tweet\" data-url=\"https://seekingalpha.com/news/3248388-sling-tv-to-start-offering-nbc-regional-sports-nets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248384\" data-ts=\"1488497994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADSK\" target=\"_blank\">ADSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248384-autodeskminus-1_8-q4-2017-over-expectations-forecasts-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autodesk -1.8%; Q4 2017 over expectations, forecasts off</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3248288-autodesk-beats-0_06-beats-revenue\" target=\"_blank\">Q4 2017 results</a></strong> &ndash; revenue $478.8M (-26.1% Y/Y,&nbsp;<font color='green'>$5.25M above estimates</font>), EPS -$0.28 (<font color='green'>$0.06 above estimates</font>), new model subscriptions 1.09M (+227K Q/Q), total subscriptions 3.11M (+154K Q/Q), new model ARR $529M (+107% Y/Y), total ARR $1.6B (+16% Y/Y), deferred revenue $1.79B (+18% Y/Y), total spend $560M (-4% Y/Y)</li><li><strong>Q1 2018 projections</strong> &ndash; revenue $460M-$480M (<a href=\"https://finance.yahoo.com/quote/ADSK/analysts?p=ADSK\" target=\"_blank\">consensus $496.65M</a>), EPS -$0.27 to -$0.21 (consensus -$0.13)</li><li><strong>FY 2017 projections</strong> &ndash; revenue $2B-$2.05B (<a href=\"https://finance.yahoo.com/quote/ADSK/analysts?p=ADSK\" target=\"_blank\">consensus $2.16B</a>), EPS -$0.73 to -$0.56 (consensus -$0.11), spend approximately unchanged, net subscription additions 600K-650K, total ARR 24%-26%</li><li><strong>After hours</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/ADSK' title='Autodesk, Inc.'>ADSK</a>) $85.75</li><li><a href=\"https://seekingalpha.com/pr/16760194-autodesk-reports-strong-fourth-quarter-results\" target=\"_blank\">Press release</a> / <a href=\"http://edge.media-server.com/m/p/xqjcqbbs/lan/en\" target=\"_blank\">conference call</a> /&nbsp;<a href=\"https://seekingalpha.com/filing/3441068\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248384\" data-linked=\"Autodesk -1.8%; Q4 2017 over expectations, forecasts off\" data-tweet=\"$ADSK - Autodesk -1.8%; Q4 2017 over expectations, forecasts off https://seekingalpha.com/news/3248384-autodeskminus-1_8-q4-2017-over-expectations-forecasts-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3248384-autodeskminus-1_8-q4-2017-over-expectations-forecasts-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248383\" data-ts=\"1488497820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVC\" target=\"_blank\">EVC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248383-entravisionplus-12_6-revenues-profits-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Entravision +12.6% as revenues, profits rise</a></h4><ul>   <li>Entravision Communications (NYSE:<a href='https://seekingalpha.com/symbol/EVC' title='Entravision Communications Corporation'>EVC</a>) has <font color='green'>jumped 12.6%</font> in after-hours trading following <a href=\"https://seekingalpha.com/news/3248328-entravision-eps-line-misses-revenue\" target=\"_blank\">Q4 earnings</a> where profits were in line, though revenues rose in all segments and the company entered a deal to buy a marketing solutions firm.</li>    <li>Entravision has a definitive deal to acquire Headway, a provider of \"mobile, programmatic, data and performance digital marketing solutions\" focused on the Western hemisphere, for cash on hand.</li>    <li>EBITDA rose 10% to $20.6M, which missed an expected $21.6M. Free cash flow rose 10%, to $14.92M, and net income was up 21% to $7M.</li>    <li>Revenue by segment: Television, $43.4M (up 9%); Radio, $20.2M (up 4%); Digital, $6.67M (up 6%).</li>    <li>The company anticipates about $264M in proceeds for its participation in the FCC's reverse spectrum auction, which it expects to receive in the second half.</li>    <li><a href=\"https://seekingalpha.com/pr/16760291-entravision-communications-corporation-reports-fourth-quarter-full-year-2016-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3248383\" data-linked=\"Entravision +12.6% as revenues, profits rise\" data-tweet=\"$EVC - Entravision +12.6% as revenues, profits rise https://seekingalpha.com/news/3248383-entravisionplus-12_6-revenues-profits-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3248383-entravisionplus-12_6-revenues-profits-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248376\" data-ts=\"1488494312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248376-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/HABT' title='The Habit Restaurants'>HABT</a> <font color='green'>+6.5%</font>. <a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/GWRE' title='Guidewire Software, Inc.'>GWRE</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/SDLP' title='Seadrill Partners, LLC'>SDLP</a> <font color='green'>+2.3%</font>. <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='green'>+2.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color='red'>-29.7%</font>. <a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='red'>-15.1%</font>. <a href='https://seekingalpha.com/symbol/IMMR' title='Immersion Corporation'>IMMR</a> <font color='red'>-13.9%</font>. <a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='red'>-13.9%</font>. BBG <font color='red'>-11.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248376\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$HABT $GFI $GWRE - After Hours Gainers / Losers https://seekingalpha.com/news/3248376-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3248376-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248373\" data-ts=\"1488493775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMR\" target=\"_blank\">IMMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248373-immersionminus-15_8-q4-2016-outlook-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immersion -15.8%; Q4 2016, outlook disappoint</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3248317-immersion-misses-0_09-misses-revenue\" target=\"_blank\">Q4 2016 results</a></strong> &ndash; revenue $9.3M (-43.9% Y/Y,&nbsp;<font color='red'>$1.36M below estimates</font>), EPS -$0.27 (<font color='red'>$0.09 below estimates</font>), royalty and license revenues $8.9M (-43% Y/Y), net loss $7.9M (vs. $2.1M net income Y/Y)</li><li><strong>Outlook commentary (CEO&nbsp;Vic Viegas)</strong>&nbsp;&ndash; \"In the near-term, we recognize that there will be some trade-offs with regards to financial performance as we vigorously defend our IP. In addition to normal considerations, our guidance for 2017 takes into account the ongoing litigation with Apple and the current unlicensed status of Samsung.\"</li><li><strong>FY 2017 projections</strong> &ndash; revenue $38M-$42M (<a href=\"https://finance.yahoo.com/quote/IMMR/analysts?p=IMMR\" target=\"_blank\">consensus $54.11M</a>), EPS -$1.05 to -$0.76 (consensus -$0.15)</li><li><strong>After hours</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMR' title='Immersion Corporation'>IMMR</a>) $9</li><li><a href=\"https://seekingalpha.com/pr/16760271-immersion-corporation-reports-fourth-quarter-full-year-2016-results\" target=\"_blank\">Press release</a> / <a href=\"http://edge.media-server.com/m/p/jxw8ncaw\" target=\"_blank\">conference call</a> / <a href=\"https://seekingalpha.com/filing/3441393\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248373\" data-linked=\"Immersion -15.8%; Q4 2016, outlook disappoint\" data-tweet=\"$IMMR - Immersion -15.8%; Q4 2016, outlook disappoint https://seekingalpha.com/news/3248373-immersionminus-15_8-q4-2016-outlook-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3248373-immersionminus-15_8-q4-2016-outlook-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248359\" data-ts=\"1488492110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248359-regulus-loses-20m-in-q4-hcv-candidate-rgminus-101-to-remain-on-clinical-hold-until-least-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus loses $20M in Q4; HCV candidate RG-101 to remain on clinical hold until at least year end; shares ease 5% after hours</a></h4><ul><li>Regulus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>) <a href=\"https://seekingalpha.com/pr/16760253-regulus-reports-fourth-quarter-2016-financial-results-pipeline-update\" target=\"_blank\">loses $20M in Q4</a>, cash balance at $76.1M (-34.0%).</li><li>Pipeline update:</li><li>Phase 2 study of RG-012 in Alport syndrome modified to include HERA study in 30 patients with rapid renal function decline. Top-line data from renal biopsy study expected in Q4, interim data from HERA expected in mid-2018.</li><li>Top-line data from the Phase 2 study of HCV candidate RG-101, in combination with Harvoni, Olysio or Daklinza, showed significant virologic response through 48 weeks of follow-up (genotypes 1 and 4). RG-101 + Harvoni showed a 100% cure rate (SVR48), RG-101 + Olysio showed 77% and RG-101 + Daklinza showed 84%. The results do not appear to demonstrate a clear treatment benefit from RG-101 compared to the companion therapies alone, however.</li><li>The clinical development program for RG-101 remains on clinical hold. The company expects to submit the requested data to the FDA in Q4.</li><li>Shares are down&nbsp;<font color='red'>5%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248359\" data-linked=\"Regulus loses $20M in Q4; HCV candidate RG-101 to remain on clinical hold until at least year end; shares ease 5% after hours\" data-tweet=\"$RGLS - Regulus loses $20M in Q4; HCV candidate RG-101 to remain on clinical hold until at least year end; shares ease 5% after hours https://seekingalpha.com/news/3248359-regulus-loses-20m-in-q4-hcv-candidate-rgminus-101-to-remain-on-clinical-hold-until-least-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3248359-regulus-loses-20m-in-q4-hcv-candidate-rgminus-101-to-remain-on-clinical-hold-until-least-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248354\" data-ts=\"1488491793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248354-marvell-technology-groupplus-1_8-q4-2017-forecasts-positive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell Technology Group +1.8%; Q4 2017, forecasts positive</a></h4><ul><li><strong>Q4 2017 results</strong> &ndash; revenue $571.4M (-7.3% Y/Y,&nbsp;<font color='green'>$3.76M above estimates</font>), EPS $0.22 (<font color='green'>$0.03 above estimates</font>), gross margin 57.6%, cash and short-term investments $1.67B</li><li><strong>Q1 2018 projections</strong> &ndash; revenue $570M (+/- 2%; <a href=\"https://finance.yahoo.com/quote/MRVL/analysts?p=MRVL\" target=\"_blank\">consensus $545.54M</a>), EPS $0.19-$0.23 (consensus $0.17), gross margin 59%, operating expenses $250M-$265M</li><li><strong>After hours</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>) $16.13</li><li><a href=\"https://seekingalpha.com/pr/16760235-marvell-technology-group-ltd-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press release</a> / <a href=\"http://edge.media-server.com/m/p/f3tw5efi/lan/en\" target=\"_blank\">conference call</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248354\" data-linked=\"Marvell Technology Group +1.8%; Q4 2017, forecasts positive\" data-tweet=\"$MRVL - Marvell Technology Group +1.8%; Q4 2017, forecasts positive https://seekingalpha.com/news/3248354-marvell-technology-groupplus-1_8-q4-2017-forecasts-positive?source=tweet\" data-url=\"https://seekingalpha.com/news/3248354-marvell-technology-groupplus-1_8-q4-2017-forecasts-positive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248350\" data-ts=\"1488491311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLDR\" target=\"_blank\">BLDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248350-builder-firstsource-backer-selling-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Builder FirstSource backer selling shares</a></h4><ul><li>The company launches <a href=\"https://seekingalpha.com/pr/16760299-builders-firstsource-inc-announces-secondary-offering\" target=\"_blank\">a secondary offering of </a>10M shares to be sold by JLL Building Holdings. After the sale JLL will own 14.3M shares of <a href='https://seekingalpha.com/symbol/BLDR' title='Builders FirstSource, Inc.'>BLDR</a>.</li><li>The sale comes after a&nbsp;<font color='green'>38% gain</font>&nbsp;YTD, and a&nbsp;<font color='green'>near-doubling</font>&nbsp;in the stock price over the past year.</li><li>Shares were initially lower on the announcement, but currently flat in thin after hours trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248350\" data-linked=\"Builder FirstSource backer selling shares\" data-tweet=\"$BLDR - Builder FirstSource backer selling shares https://seekingalpha.com/news/3248350-builder-firstsource-backer-selling-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3248350-builder-firstsource-backer-selling-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248345\" data-ts=\"1488490905\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KPTI\" target=\"_blank\">KPTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248345-karyopharms-lead-product-candidate-flunks-mid-stage-aml-study-shares-slump-11-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karyopharm&#39;s lead product candidate flunks mid-stage AML study; shares slump 11% after hours</a></h4><ul><li>An <a href=\"https://seekingalpha.com/pr/16760224-karyopharm-announces-results-interim-analysis-phase-2-sopra-study-evaluating-selinexor\" target=\"_blank\">interim analysis</a> of a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02088541?term=selinexor&amp;phase=1&amp;rank=18\" target=\"_blank\">SOPRA</a>, assessing Karyopharm Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a>) lead product candidate selinexor in patients with treatment-resistant acute myeloid leukemia &#40;AML&#41; showed that the study was unlikely to show a treatment benefit over physician choice &#40;PC&#41;&nbsp;as measured by overall survival &#40;OS&#41;, the primary endpoint.</li><li>Complete responders did show a substantial OS benefit over PC so these patients will be permitted to continue in the study as agreed by the company and the independent Data Safety Monitoring Board.</li><li>The company remains undeterred by the setback. It says it will continue developing selinexor in AML though investigator-sponsored trials in multiple combination regimens, including chemo.</li><li><a href=\"http://karyopharm.com/drug-candidate/oral_selinexor_kpt-330/\" target=\"_blank\">Selinexor&nbsp;</a>is a SINE (Selective Inhibitor of Nuclear Export) compound. It binds to and inhibits the nuclear export protein XPO1 which leads to the accumulation of tumor suppressor proteins in the cell nucleus which amplifies tumor suppression. It is also under development for the treatment of liposarcoma, diffuse large B-cell lymphoma and multiple myeloma.</li><li>Shares are down&nbsp;<font color='red'>11%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248345\" data-linked=\"Karyopharm&#39;s lead product candidate flunks mid-stage AML study; shares slump 11% after hours\" data-tweet=\"$KPTI - Karyopharm&#39;s lead product candidate flunks mid-stage AML study; shares slump 11% after hours https://seekingalpha.com/news/3248345-karyopharms-lead-product-candidate-flunks-mid-stage-aml-study-shares-slump-11-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3248345-karyopharms-lead-product-candidate-flunks-mid-stage-aml-study-shares-slump-11-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248344\" data-ts=\"1488490871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248344-nutanixminus-15-q2-2017-over-consensus-outlook-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix -15%; Q2 2017 over consensus, outlook off</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3248289-nutanix-beats-0_07-beats-revenue\" target=\"_blank\">Q2 2017 results</a></strong> &ndash; revenue $182.2M (+77.4% Y/Y,&nbsp;<font color='green'>$3.82M above estimates</font>), EPS -$0.28 (<font color='green'>$0.07 above estimates</font>), billings $227.4M (+59% Y/Y), net loss $39.9M (vs. $30.9M net loss Y/Y), cash and short-term investments $355.2M (+175% Y/Y), deferred revenue $420.6M (+128% Y/Y), operating cash flow $19.8M (vs. $4.5M Y/Y), free cash flow $7.1M (vs. -$5.9M Y/Y)</li><li><strong>Q3 2017 projections</strong> &ndash; revenue $180M-$190M (<a href=\"https://finance.yahoo.com/quote/NTNX/analysts?p=NTNX\" target=\"_blank\">consensus $188.45M</a>), EPS -$0.45 to -$0.48 (consensus -$0.35), gross margin 57%-58%</li><li><strong>After hours</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) $26.40</li><li><a href=\"https://seekingalpha.com/pr/16760201-nutanix-reports-second-quarter-fiscal-2017-financial-results\" target=\"_blank\">Press release</a> / <a href=\"https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;referrer=http%3A%2F%2Fir.nutanix.com%2Fcompany%2Ffinancial%2F&amp;eventid=1355018&amp;sessionid=1&amp;key=C58705D6B790D5732C277CB2F42FDA08&amp;regTag=&amp;sourcepage=register\" target=\"_blank\">conference call</a> / <a href=\"https://seekingalpha.com/filing/3441243\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248344\" data-linked=\"Nutanix -15%; Q2 2017 over consensus, outlook off\" data-tweet=\"$NTNX - Nutanix -15%; Q2 2017 over consensus, outlook off https://seekingalpha.com/news/3248344-nutanixminus-15-q2-2017-over-consensus-outlook-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3248344-nutanixminus-15-q2-2017-over-consensus-outlook-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248342\" data-ts=\"1488490812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBB\" target=\"_blank\">CBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248342-cincinnati-bell-ceo-retiring-fox-named-to-take-over\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cincinnati Bell CEO retiring; Fox named to take over</a></h4><ul>   <li>Cincinnati Bell (<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a> <font color='red'>-3.3%</font>) says its CEO Ted Torbeck will <a href=\"https://seekingalpha.com/pr/16760292-ted-torbeck-retire-leigh-fox-named-ceo-cincinnati-bell-inc\" target=\"_blank\">retire May 31</a>, and has tapped Leigh Fox to replace him.</li>    <li>Fox will take over as president and chief executive on May 31. Torbeck, 60, will remain on the board and work toward a smooth transition of duties.</li>    <li>Fox joined the firm in 2001. He's currently president and chief operating officer, and has previously held roles including chief financial officer, chief administrative officer, and other financial roles.</li>    <li>The company also reaffirmed 2017 guidance for revenues of $1.2B and EBITDA of $289.1M-$300.9M, both in line with consensus expectations.</li>    <li>After hours, shares are <font color='green'>up 0.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248342\" data-linked=\"Cincinnati Bell CEO retiring; Fox named to take over\" data-tweet=\"$CBB - Cincinnati Bell CEO retiring; Fox named to take over https://seekingalpha.com/news/3248342-cincinnati-bell-ceo-retiring-fox-named-to-take-over?source=tweet\" data-url=\"https://seekingalpha.com/news/3248342-cincinnati-bell-ceo-retiring-fox-named-to-take-over\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248341\" data-ts=\"1488490598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COST\" target=\"_blank\">COST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248341-u-s-sales-steady-for-costco-membership-fee-increase-on-way\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. sales steady for Costco, membership fee increase on the way</a></h4><ul><li>Costco (NASDAQ:<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a>) reports a 3% increase in comparable sales in FQ2.</li><li>Comparable sales were higher in the U.S. (+3%) and Canada (+8%) during the quarter, but fell off in international markets (-2%).</li><li>For the four weeks ending February 26 (into FQ3), comparable sales in the U.S. were up 5% and the total comparable sales rose 4%.</li><li>The company announces that it will push through a $5 price increase to new members on June 1.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248316-costco-wholesale-misses-0_19-misses-revenue\" target=\"_blank\">Costco Wholesale misses by $0.19, misses on revenue</a> (March 2)</li><li>COST&nbsp;<font color='red'>-4.96%</font>&nbsp;AH to $169.16.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248341\" data-linked=\"U.S. sales steady for Costco, membership fee increase on the way\" data-tweet=\"$COST - U.S. sales steady for Costco, membership fee increase on the way https://seekingalpha.com/news/3248341-u-s-sales-steady-for-costco-membership-fee-increase-on-way?source=tweet\" data-url=\"https://seekingalpha.com/news/3248341-u-s-sales-steady-for-costco-membership-fee-increase-on-way\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248330\" data-ts=\"1488489913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCYX\" target=\"_blank\">SCYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248330-scynexis-iv-scyminus-078-on-clinical-hold-pending-investigation-of-adverse-events-in-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCYNEXIS&#39; IV SCY-078 on clinical hold pending investigation of adverse events in early-stage study; shares down 31% after hours</a></h4><ul><li>The FDA has informed SCYNEXIS (NASDAQ:<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a>) to <a href=\"https://seekingalpha.com/pr/16760232-scynexis-delays-initiation-new-clinical-studies-using-iv-formulation-scyminus-078-fda-s\" target=\"_blank\">delay the initiation</a> of any clinical trials assessing the intravenous &#40;IV&#41; formulation of lead product candidate SCY-078 until it completes the review of all available pre-clinical and clinical data on the IV formulation. The clinical hold was instituted after three mild-to-moderate thrombotic events were observed in a Phase 1 study in healthy volunteers.</li><li>The company intends to meet with the agency next quarter to discuss the data and agree on subsequent studies.</li><li>Clinical trials, present and future, assessing the oral formulation of SCY-078 are unaffected.</li><li><a href=\"http://www.scynexis.com/pipeline/pipeline.php\" target=\"_blank\">SCY-078</a>&nbsp;inhibits an enzyme called&nbsp;<a href=\"https://en.wikipedia.org/wiki/1,3-Beta-glucan_synthase\" target=\"_blank\">glucan synthase</a>. Its value proposition is comparable activity to echinocandins [e.g., Astellas'&nbsp;<a href=\"https://www.mycamine.com/\" target=\"_blank\">Mycamine&nbsp;</a>(micafungin sodium) for injection] but available in an oral formulation and active against multi-drug-resistant pathogens, including those resistant to echinocandins.</li><li>Shares are off&nbsp;<font color='red'>31%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248330\" data-linked=\"SCYNEXIS&#39; IV SCY-078 on clinical hold pending investigation of adverse events in early-stage study; shares down 31% after hours\" data-tweet=\"$SCYX - SCYNEXIS&#39; IV SCY-078 on clinical hold pending investigation of adverse events in early-stage study; shares down 31% after hours https://seekingalpha.com/news/3248330-scynexis-iv-scyminus-078-on-clinical-hold-pending-investigation-of-adverse-events-in-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3248330-scynexis-iv-scyminus-078-on-clinical-hold-pending-investigation-of-adverse-events-in-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248313\" data-ts=\"1488489394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248313-margins-improve-american-outdoor-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Margins improve at American Outdoor Brands</a></h4><ul>     <li>American Outdoor Brands Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a>) reports gross margin increased 140 bps to 42.5% of sales during <a href=\"https://seekingalpha.com/pr/16760226-american-outdoor-brands-corporation-reports-third-quarter-fiscal-2017-financial-results\" target=\"_blank\">FQ4</a>. Analysts expected a mark of 40.0%.</li>     <li>The company says operating cash flow during the quarter was $48.2M.</li><li>American Outdoor also invested $33.0M through acquisitions in Q4 and paid off $25M from a&nbsp;line of credit.</li><li>Looking ahead, American Outdoor sees FQ1 revenue of $200M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248301-american-outdoor-brands-beats-0_11-misses-revenue\" target=\"_blank\">American Outdoor Brands beats by $0.11, misses on revenue</a> (March 2)</li><li>AOBC&nbsp;<font color='red'>-4.33%</font>&nbsp;AH to $18.54.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248313\" data-linked=\"Margins improve at American Outdoor Brands\" data-tweet=\"$AOBC - Margins improve at American Outdoor Brands https://seekingalpha.com/news/3248313-margins-improve-american-outdoor-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3248313-margins-improve-american-outdoor-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248309\" data-ts=\"1488489322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248309-brazil-tumbles-despite-dovish-central-bank-message\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil tumbles despite dovish central bank message</a></h4><ul><li><a href=\"http://www.nasdaq.com/article/update-2brazil-central-bank-could-speed-up-rate-cuts-depending-on-economy-inflation-20170302-01025\" target=\"_blank\">The minutes from</a> last month's policy meeting (at which the benchmark Selic rate was slashed 75 basis points to 12.25%) show the central bank willing to speed up the pace of rate cuts if inflation and the economy cooperate.</li><li>The next meeting is in April, and most expect another 75 basis point move, but the probability of 100 is on the rise, says Goldman's Alberto Ramos.</li><li>The real fell, as did the Bovespa,&nbsp;<font color='red'>-1.85%</font>.</li><li><a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a>&nbsp;<font color='red'>-4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a>, <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a>, <a href='https://seekingalpha.com/symbol/BRZU' title='Direxion Daily Brazil Bull 3x Shares ETF'>BRZU</a>, <a href='https://seekingalpha.com/symbol/EWZS' title='iShares MSCI Brazil Small-Cap ETF'>EWZS</a>, <a href='https://seekingalpha.com/symbol/BZQ' title='ProShares UltraShort MSCI Brazil Capped ETF'>BZQ</a>, <a href='https://seekingalpha.com/symbol/BRAQ' title='Global X Brazil Consumer ETF'>BRAQ</a>, <a href='https://seekingalpha.com/symbol/BRAZ' title='Global X Brazil Mid-Cap ETF'>BRAZ</a>, <a href='https://seekingalpha.com/symbol/UBR' title='ProShares Ultra MSCI Brazil Capped ETF'>UBR</a>, <a href='https://seekingalpha.com/symbol/DBBR' title='Deutsche X-trackers MSCI Brazil Hedged Equity ETF'>DBBR</a>, <a href='https://seekingalpha.com/symbol/FBZ' title='First Trust Brazil AlphaDEX ETF'>FBZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248309\" data-linked=\"Brazil tumbles despite dovish central bank message\" data-tweet=\"$EWZ $BRF $BRZU - Brazil tumbles despite dovish central bank message https://seekingalpha.com/news/3248309-brazil-tumbles-despite-dovish-central-bank-message?source=tweet\" data-url=\"https://seekingalpha.com/news/3248309-brazil-tumbles-despite-dovish-central-bank-message\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248307\" data-ts=\"1488489227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248307-regulus-therapeutics-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus Therapeutics misses by $0.01, misses on revenue</a></h4><ul><li>Regulus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>): Q4 EPS of -$0.38 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $0.02M vs. $10.86M in 4Q15.</li><li>Shares <font color='green'>+4.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16760253-regulus-reports-fourth-quarter-2016-financial-results-pipeline-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248307\" data-linked=\"Regulus Therapeutics misses by $0.01, misses on revenue\" data-tweet=\"$RGLS - Regulus Therapeutics misses by $0.01, misses on revenue https://seekingalpha.com/news/3248307-regulus-therapeutics-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3248307-regulus-therapeutics-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248304\" data-ts=\"1488489131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRX\" target=\"_blank\">ACRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248304-acelrx-q4-beats-consensus-shares-ahead-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AcelRx Q4 beats consensus; shares ahead 5% after hours</a></h4><ul><li>AcelRx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>) <a href=\"https://seekingalpha.com/pr/16760193-acelrx-pharmaceuticals-reports-fourth-quarter-year-end-2016-financial-results\" target=\"_blank\">Q4 results</a> ($M): Revenues: 6.4 (+272.0%).</li><li>Net Loss: (9.7) (+8.2%); Loss/Share: (0.21) (+12.5%); Quick Assets: 80.3 (-29.3%).</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;after hours but only on 300 shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248297-acelrx-pharmaceuticals-beats-0_03-beats-revenue\" target=\"_blank\">AcelRx Pharmaceuticals beats by $0.03, beats on revenue</a> (March 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248304\" data-linked=\"AcelRx Q4 beats consensus; shares ahead 5% after hours\" data-tweet=\"$ACRX - AcelRx Q4 beats consensus; shares ahead 5% after hours https://seekingalpha.com/news/3248304-acelrx-q4-beats-consensus-shares-ahead-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3248304-acelrx-q4-beats-consensus-shares-ahead-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248302\" data-ts=\"1488489026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248302-syndax-pharmaceuticals-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax Pharmaceuticals beats by $0.11, beats on revenue</a></h4><ul><li>Syndax Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a>): Q4 EPS of -$0.59 <font color='green'>beats by $0.11</font>.</li><li>Revenue of $0.3M (flat Y/Y) <font color='green'>beats by $0.15M</font>.</li><li>Shares <font color='green'>+7.7%</font>.</li><li><a href='https://seekingalpha.com/pr/16760241-syndax-pharmaceuticals-reports-fourth-quarter-year-end-2016-financial-results-provides'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248302\" data-linked=\"Syndax Pharmaceuticals beats by $0.11, beats on revenue\" data-tweet=\"$SNDX - Syndax Pharmaceuticals beats by $0.11, beats on revenue https://seekingalpha.com/news/3248302-syndax-pharmaceuticals-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3248302-syndax-pharmaceuticals-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248290\" data-ts=\"1488488741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248290-prothena-readies-2_7m-share-equity-offering-shares-ease-fraction-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prothena readies 2.7M-share equity offering; shares ease a fraction after hours</a></h4><ul><li>Prothena (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a>) <a href=\"https://seekingalpha.com/pr/16760198-prothena-announces-public-offering-ordinary-shares\" target=\"_blank\">commences </a>a public offering of 2.7M shares of common stock. Underwriters over-allotment is an additional 405K shares. Price and terms have yet to be announced.</li><li>Shares are off a fraction after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248290\" data-linked=\"Prothena readies 2.7M-share equity offering; shares ease a fraction after hours\" data-tweet=\"$PRTA - Prothena readies 2.7M-share equity offering; shares ease a fraction after hours https://seekingalpha.com/news/3248290-prothena-readies-2_7m-share-equity-offering-shares-ease-fraction-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3248290-prothena-readies-2_7m-share-equity-offering-shares-ease-fraction-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248282\" data-ts=\"1488486916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTI\" target=\"_blank\">WTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248282-w-and-t-offshoreplus-10-after-surprise-q4-profit-sees-125m-in-2017-capex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W&amp;T Offshore +10% after surprise Q4 profit; sees $125M in 2017 capex</a></h4><ul>     <li>W&amp;T&nbsp;Offshore (<a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+10.3%</font>) surges after easily beating <a href=\"https://seekingalpha.com/news/3247945-w-and-amp-t-offshore-beats-0_19-misses-revenue\" target=\"_blank\">Q4 earnings</a> expectations while posting its first adjusted profit in at least eight quarters.</li><li>WTI says Q4 production fell 10% Y/Y to 40.3K boe/day (55% oil and natural gas liquids) but revenues rose nearly 11%, as the $30.83/boe average realized sales price was 24% higher than $24.84/boe in the year-ago quarter.</li>     <li>Looking ahead, WTI expects ~$125M in FY 2017 capex, far exceeding its 2016 capex of $48.6M on an accrual basis and $83.8M on a cash basis; FY 2015 capex was $230M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248282\" data-linked=\"W&amp;T Offshore +10% after surprise Q4 profit; sees $125M in 2017 capex\" data-tweet=\"$WTI - W&amp;T Offshore +10% after surprise Q4 profit; sees $125M in 2017 capex https://seekingalpha.com/news/3248282-w-and-t-offshoreplus-10-after-surprise-q4-profit-sees-125m-in-2017-capex?source=tweet\" data-url=\"https://seekingalpha.com/news/3248282-w-and-t-offshoreplus-10-after-surprise-q4-profit-sees-125m-in-2017-capex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248281\" data-ts=\"1488486910\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVB\" target=\"_blank\">NAVB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248281-navidea-shareholders-ok-sale-of-lymphoseek-sale-to-cardinal-shares-up-29\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navidea shareholders OK sale of Lymphoseek sale to Cardinal; shares up 29%</a></h4><ul><li>At a special meeting held today, Navidea Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/NAVB' title='Navidea Biopharmaceuticals'>NAVB</a> <font color='green'>+29.3%</font>) shareholders <a href=\"https://seekingalpha.com/filing/3440404\" target=\"_blank\">overwhelmingly backed</a> the proposed the sale of Lymphoseek to Cardinal Health (<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a> <font color='red'>-0.2%</font>).</li><li>Under the terms of the deal, Navidea will receive $80M at closing and up to $230M in milestones through 2026, with $20.1M guaranteed over the next three years.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3226766-navidea-sells-lymphoseek-cardinal-health-310m-shares-5-percent\" target=\"_blank\">Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%</a> (Nov. 23, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248281\" data-linked=\"Navidea shareholders OK sale of Lymphoseek sale to Cardinal; shares up 29%\" data-tweet=\"$NAVB $NAVB $CAH - Navidea shareholders OK sale of Lymphoseek sale to Cardinal; shares up 29% https://seekingalpha.com/news/3248281-navidea-shareholders-ok-sale-of-lymphoseek-sale-to-cardinal-shares-up-29?source=tweet\" data-url=\"https://seekingalpha.com/news/3248281-navidea-shareholders-ok-sale-of-lymphoseek-sale-to-cardinal-shares-up-29\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248280\" data-ts=\"1488486195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RF\" target=\"_blank\">RF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248280-investors-take-profits-in-financials\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors take some profits in financials</a></h4><ul><li>Satiated bulls are doing some selling today, with the regional banking sector (<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> <font color='red'>-2.4%</font>) being hit the hardest (it's still&nbsp;<font color='green'>higher by 56%</font>&nbsp;Y/Y).</li><li>With opinion about a March rate hike having swung in the past handful of days from \"no chance\" to \"sure thing,\" it's probably not a bad idea to take some profits. There's still the February employment report to come (next Friday, not tomorrow), and a weak one could quickly dial back hopes for higher rates.</li><li>Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-3.6%</font>), New York Community (<a href='https://seekingalpha.com/symbol/NYCB' title='New York Community Bancorp Inc.'>NYCB</a> <font color='red'>-2.6%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-2.4%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='red'>-2.5%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='red'>-3.3%</font>), SunTrust (<a href='https://seekingalpha.com/symbol/STI' title='SunTrust Banks, Inc.'>STI</a> <font color='red'>-2.6%</font>), M&amp;T (<a href='https://seekingalpha.com/symbol/MTB' title='M&T Bank Corporation'>MTB</a> <font color='red'>-3.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248280\" data-linked=\"Investors take some profits in financials\" data-tweet=\"$RF $KRE $RF - Investors take some profits in financials https://seekingalpha.com/news/3248280-investors-take-profits-in-financials?source=tweet\" data-url=\"https://seekingalpha.com/news/3248280-investors-take-profits-in-financials\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248279\" data-ts=\"1488485862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248279-nomura-pivotal-research-negative-on-snap-amid-trading-debut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura, Pivotal Research negative on Snap amid trading debut</a></h4><ul><li><a href=\"http://www.cnbc.com/2017/03/02/another-sell-rating-for-snap-from-wall-street-on-its-slowing-user-growth-high-valuation.html\" target=\"_blank\">Analyst Anthony DiClemente</a> (Nomura Instinet) sets Snap at Reduce, with a $16 price target, noting slowing rates of user growth and monetization, aggressive competition (Facebook, WhatsApp, Instagram specifically) and a valuation observed too expensive relative to present and future growth.</li><li>Issuing $10 target, <a href=\"http://blogs.barrons.com/techtraderdaily/2017/03/02/snap-sell-says-pivotal-10-target-based-on-2023s-6-7b-rev/\" target=\"_blank\">analyst Brian Wieser</a> (Pivotal Research) iterates similar concerns, among others (steep expenses and cash costs, \"sub-optimal corporate structure,\" dilutive share issuances, lack of voting rights). Further:&nbsp;\"Investors in Snap will be exposed to an upstart facing aggressive competition from much larger companies, with a core user base that is not growing by much and which is only relatively elusive. It has a promising and innovative advertising offering, but so far it is still mostly unproven and difficult to quantify its ultimate scale.\" Rates shares at Sell.</li><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) $25.06,&nbsp;<font color='green'>+47.41%</font>&nbsp;above $17 offering price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248279\" data-linked=\"Nomura, Pivotal Research negative on Snap amid trading debut\" data-tweet=\"$SNAP - Nomura, Pivotal Research negative on Snap amid trading debut https://seekingalpha.com/news/3248279-nomura-pivotal-research-negative-on-snap-amid-trading-debut?source=tweet\" data-url=\"https://seekingalpha.com/news/3248279-nomura-pivotal-research-negative-on-snap-amid-trading-debut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248276\" data-ts=\"1488485725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248276-intrexon-shrugs-off-early-session-sell-off-after-q4-miss-money-flow-turns-positive-over\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon shrugs off early-session sell-off after Q4 miss, money flow turns positive over advancement of multiple businesses; shares ahead 8%</a></h4><ul><li>Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='green'>+7.7%</font>) is flexing some muscle as the close approaches. Shares reversed from an early morning sell-off after Q4 results fell shy of consensus but are now poised to finish in the green on almost triple normal volume.</li><li>The positive money flow is apparently being stoked by optimism over the company's <a href=\"https://seekingalpha.com/article/4051266-intrexons-xon-ceo-randal-kirk-q4-2016-results-earnings-call-transcript\" target=\"_blank\">advancements </a>in its Oxitec, Okanagan and AquaBounty businesses. Key developments:</li><li>Oxitec: Large-scale mosquito production facility opened in Brazil. Commitment for site's egg capacity this year expected. Friendly Aedes project in Piracicaba expanded. Roll-out in Cayman Islands underway. Open-field trial of self-limiting Mediterranean fruit fly in Australia moving forward.</li><li>Okanagan: First commercial harvest of non-browning Arctic Golden apples completed. Commercial launch in selected North American markets to commence this fall. Management believes it could be a $1B business.</li><li>AquaBounty: Recently approved by a number of large distributors. Construction of first U.S. facility expected to commence this year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3247923-intrexon-misses-0_14-misses-revenue\" target=\"_blank\">Intrexon misses by $0.14, misses on revenue</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248276\" data-linked=\"Intrexon shrugs off early-session sell-off after Q4 miss, money flow turns positive over advancement of multiple businesses; shares ahead 8%\" data-tweet=\"$XON - Intrexon shrugs off early-session sell-off after Q4 miss, money flow turns positive over advancement of multiple businesses; shares ahead 8% https://seekingalpha.com/news/3248276-intrexon-shrugs-off-early-session-sell-off-after-q4-miss-money-flow-turns-positive-over?source=tweet\" data-url=\"https://seekingalpha.com/news/3248276-intrexon-shrugs-off-early-session-sell-off-after-q4-miss-money-flow-turns-positive-over\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248274\" data-ts=\"1488484824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248274-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/ACIW' title='ACI Worldwide, Inc.'>ACIW</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ICLD-OLD' title='InterCloud Systems, Inc.'>ICLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ANGI' title='ANGI Homeservices Inc.'>ANGI</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/KVHI' title='KVH Industries, Inc.'>KVHI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/UNXL' title='Uni-Pixel, Inc.'>UNXL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248274\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$SNAP $ACIW $RNVA - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3248274-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3248274-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248272\" data-ts=\"1488483841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNP\" target=\"_blank\">SNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248272-sinopec-to-spend-29b-in-upgrading-four-refining-bases\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinopec to spend $29B in upgrading four refining bases</a></h4><ul>     <li>China's Sinopec (<a href='https://seekingalpha.com/symbol/SNP' title='China Petroleum & Chemical Corporation'>SNP</a> <font color='red'>-1.9%</font>) says it will <a href=\"http://www.reuters.com/article/us-china-sinopec-idUSKBN1690UB\" target=\"_blank\">invest 200B yuan ($29B) to upgrade four refining bases</a> by 2020 to produce higher-quality fuels.</li>     <li>SNP says the total refining capacity of the four refining sites will reach 130M metric tons/year, or 2.6M bbl/day, while ethylene capacity will reach 9M metric tons/year after the upgrades.</li>     <li>The bases will make up 4% of the company's total refining capacity and 65% of its ethylene capacity after the expansion, SNP says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248272\" data-linked=\"Sinopec to spend $29B in upgrading four refining bases\" data-tweet=\"$SNP - Sinopec to spend $29B in upgrading four refining bases https://seekingalpha.com/news/3248272-sinopec-to-spend-29b-in-upgrading-four-refining-bases?source=tweet\" data-url=\"https://seekingalpha.com/news/3248272-sinopec-to-spend-29b-in-upgrading-four-refining-bases\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248270\" data-ts=\"1488483133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNQ\" target=\"_blank\">CNQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248270-canadian-natural-resourcesplus-6-after-cruising-past-q4-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Natural Resources +6% after cruising past Q4 estimates</a></h4><ul>     <li>Canadian Natural Resources (<a href='https://seekingalpha.com/symbol/CNQ' title='Canadian Natural Resources, Ltd.'>CNQ</a> <font color='green'>+6%</font>) rallies after <a href=\"https://seekingalpha.com/news/3247981-canadian-natural-resources-reports-q4-results\" target=\"_blank\">Q4 earnings</a> easily exceeded expectations, and funds flow from operations rose to C$1.68B from C$1.38B in the year-earlier ago.</li>     <li>CNQ says strong production and record low operating costs are <a href=\"http://www.reuters.com/article/cdn-natural-rsc-results-idUSL3N1GF3H6\" target=\"_blank\">driving its cash flow</a>, which it targets to exceed capex by ~C$230M (US$172M) per month.</li>     <li>The company says Q4 oil and gas production inched higher to ~859K boe/day from 856K boe/day, but average realized prices before hedging rose by nearly a third Y/Y for crude oil and 6% for natural gas, and Q4 operating costs were a  record low C$22.53/bbl.</li>     <li>CNQ forecasts FY 2017 production of 550K-590K bbl/day of crude oil and natural gas liquids and 1,700-1,760 MMcf/day  of natural gas, before royalties.</li>     <li>In its earnings conference call, CNQ said it probably is <a href=\"http://www.reuters.com/article/cdn-natural-rsc-transcanada-natgas-idUSL2N1GF1DR\" target=\"_blank\">interested in shipping natural gas</a> under TransCanada's (<a href='https://seekingalpha.com/symbol/TRP' title='TransCanada Corporation'>TRP</a> <font color='green'>+0.1%</font>) new flat toll for its Mainline system, but it has not yet made a firm decision.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248270\" data-linked=\"Canadian Natural Resources +6% after cruising past Q4 estimates\" data-tweet=\"$CNQ $CNQ $TRP - Canadian Natural Resources +6% after cruising past Q4 estimates https://seekingalpha.com/news/3248270-canadian-natural-resourcesplus-6-after-cruising-past-q4-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3248270-canadian-natural-resourcesplus-6-after-cruising-past-q4-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248269\" data-ts=\"1488483115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSI\" target=\"_blank\">SSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248269-trading-halt-on-stage-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading halt on Stage Stores</a></h4><ul><li>Trading has been halted on Stage Stores (<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-8%</font>) by the exchange.</li><li>The <a href=\"http://www.nasdaqtrader.com/Trader.aspx?id=Tradehalts\" target=\"_blank\">Nasdaq halt code</a> indicates that a news announcement is pending.</li><li>Earlier today a 13D filed by HMA Acquisition raised some eyebrows.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248202-volatile-trading-stage-stores\" target=\"_blank\">Volatile trading on Stage Stores</a> (March 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248269\" data-linked=\"Trading halt on Stage Stores\" data-tweet=\"$SSI - Trading halt on Stage Stores https://seekingalpha.com/news/3248269-trading-halt-on-stage-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3248269-trading-halt-on-stage-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248265\" data-ts=\"1488481832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248265-golds-bull-run-on-two-week-breather\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold&#39;s bull run on two-week breather</a></h4><ul><li>The metal&nbsp;<font color='red'>dipped another 1.35%</font>&nbsp;today to $1,233 per ounce, its lowest level in two weeks, but <a href=\"http://finviz.com/futures_charts.ashx?p=d1&amp;t=GC\" target=\"_blank\">only a large blip</a> on a bounce that had previously taken the price from $1,130 per ounce in mid-December to $1,260 in mid-February.</li><li>The decline comes alongside a fast ratchet upward in rate hike expectations, with even <a href=\"https://seekingalpha.com/news/3248147-fed-dove-rate-hike-appropriate-soon\" target=\"_blank\">a Fed dove hinting</a> that the next FOMC move is coming this month.</li><li><a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>&nbsp;<font color='red'>-1.4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='ETFS Physical Swiss Gold Trust ETF'>SGOL</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='PowerShares DB Gold ETF'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248265\" data-linked=\"Gold&#39;s bull run on two-week breather\" data-tweet=\"$GLD $IAU $PHYS - Gold&#39;s bull run on two-week breather https://seekingalpha.com/news/3248265-golds-bull-run-on-two-week-breather?source=tweet\" data-url=\"https://seekingalpha.com/news/3248265-golds-bull-run-on-two-week-breather\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248263\" data-ts=\"1488481396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248263-highlights-from-krogers-earnings-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Highlights from Kroger&#39;s earnings call</a></h4><ul><li>Execs with Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='red'>-3.5%</font>) say the company is open to M&amp;A, but isn't actively seeking out a deal.</li><li>They also pointed to rising labor, pension and health care costs as drags on earnings, while noting pricing could work in its favor during the second half.</li><li>The company plans to increase its investment in digital in order to connect with customers. Early success with the online ordering ClickList is mentioned.</li><li><a href=\"http://services.choruscall.com/links/kr170302.html\" target=\"_blank\">Kroger earnings call webcast</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3248064-kroger-beats-0_01-beats-revenue\" target=\"_blank\">Kroger beats by $0.01, beats on revenue</a> (March 2)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248076-kroger-mark-profit-guidance\" target=\"_blank\">Kroger on the mark with profit guidance</a> (March 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248263\" data-linked=\"Highlights from Kroger&#39;s earnings call\" data-tweet=\"$KR - Highlights from Kroger&#39;s earnings call https://seekingalpha.com/news/3248263-highlights-from-krogers-earnings-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3248263-highlights-from-krogers-earnings-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248262\" data-ts=\"1488481342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248262-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SDLP' title='Seadrill Partners, LLC'>SDLP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CNQ' title='Canadian Natural Resources, Ltd.'>CNQ</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/FSM' title='Fortuna Silver Mines'>FSM</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SSRI' title='SSR Mining Inc'>SSRI</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248262\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$WTI $SDLPF $CNQ - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3248262-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3248262-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248389\" data-ts=\"1488480907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUBCY\" target=\"_blank\">SUBCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248389-subsea-7-surges-to-four-year-highs-on-q4-beat-special-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Subsea 7 surges to four-year highs on Q4 beat, special dividend</a></h4><ul>     <li>Subsea 7 (<a href='https://seekingalpha.com/symbol/SUBCY' title='Subsea 7 S.A. ADR'>OTCPK:SUBCY</a> <font color='green'>+3.9%</font>) reported <a href=\"http://www.reuters.com/article/subsea-results-idUSL5N1GF2VA\" target=\"_blank\">better than expected Q4 earnings</a> earlier today along with plans to pay a special dividend, sending shares to their highest level in four years in Oslo trading.</li>     <li>The Pareto brokerage says strong project execution and the first dividend payment since 2013 helped to trigger the positive reaction; however, Bernstein analysts maintained their Underperform rating, saying Subsea 7's prospects remain uncertain even after the solid quarter.</li>     <li>Subsea 7 reported Q4 adjusted EBITDA of $288M, more than 50% better than the analyst consensus forecast of $187M</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248389\" data-linked=\"Subsea 7 surges to four-year highs on Q4 beat, special dividend\" data-tweet=\"$SUBCY - Subsea 7 surges to four-year highs on Q4 beat, special dividend https://seekingalpha.com/news/3248389-subsea-7-surges-to-four-year-highs-on-q4-beat-special-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3248389-subsea-7-surges-to-four-year-highs-on-q4-beat-special-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248257\" data-ts=\"1488480332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HGG\" target=\"_blank\">HGG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248257-best-buy-rallies-after-hhgregg-shrinks-retail-footprint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy rallies after hhgregg shrinks retail footprint</a></h4><ul>     <li>Retailer hhgregg (<a href='https://seekingalpha.com/symbol/HGG' title='hhgregg, Inc.'>HGG</a>) says it will close 88 stores as it looks to fend off bankruptcy.</li>     <li>\"We are strategically exiting markets and stores that are not financially profitable for us,\" says CEO&nbsp;Robert Riesbeck.</li>     <li>Three distribution centers will also be shuttered.</li><li>Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='green'>+6.5%</font>) is higher in a possible reaction to the development. The retail sector is also having a solid day across the board.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248186-relief-rally-retail-stocks\" target=\"_blank\">Relief rally for retail stocks</a> (March 2)</li>     <li><a href=\"http://ir.hhgregg.com/releases.cfm\" target=\"_blank\">hhgregg press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3248257\" data-linked=\"Best Buy rallies after hhgregg shrinks retail footprint\" data-tweet=\"$HGG $HGG $BBY - Best Buy rallies after hhgregg shrinks retail footprint https://seekingalpha.com/news/3248257-best-buy-rallies-after-hhgregg-shrinks-retail-footprint?source=tweet\" data-url=\"https://seekingalpha.com/news/3248257-best-buy-rallies-after-hhgregg-shrinks-retail-footprint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248254\" data-ts=\"1488478802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KPTI\" target=\"_blank\">KPTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248254-animal-spirits-continue-in-biotech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Animal spirits continue in biotech</a></h4><ul><li>A trio of players announcing presentations of preclinical data at the American Association for Cancer Research in early April are among the sector movers today: <a href=\"https://seekingalpha.com/pr/16758861-karyopharm-announces-presentation-new-data-2017-american-association-cancer-research-annual\" target=\"_blank\">Karyopharm Therapeutics </a>(<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='green'>+23%</font>), <a href=\"https://seekingalpha.com/pr/16758695-immunogen-announces-presentations-aacr-annual-meeting\" target=\"_blank\">ImmunoGen</a> (<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+11%</font>), <a href=\"https://seekingalpha.com/pr/16758801-affimed-present-data-immune-cell-engagers-aacr-annual-meeting-2017\" target=\"_blank\">Affimed</a> (<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='green'>+4.8%</font>).</li><li>The <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>'s&nbsp;<font color='green'>0.85% advance</font>&nbsp;this session puts that ETF higher by&nbsp;<font color='green'>nearly 5%</font>&nbsp;on the week and&nbsp;<font color='green'>15%</font>&nbsp;YTD. The <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> today is&nbsp;<font color='green'>up marginally</font>&nbsp;vs. the S&amp;P 500's&nbsp;<font color='red'>0.4% decline</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a>, <a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a>, <a href='https://seekingalpha.com/symbol/HQL' title='Tekla Life Sciences Investors'>HQL</a>, <a href='https://seekingalpha.com/symbol/PBE' title='Invesco Dynamic Biotechnology & Genome Portfolio ETF'>PBE</a>, <a href='https://seekingalpha.com/symbol/LABU' title='Direxion Daily S&P Biotech Bull 3x Shares ETF'>LABU</a>, <a href='https://seekingalpha.com/symbol/BBC' title='BioShares Biotechnology Clinical Trials ETF'>BBC</a>, <a href='https://seekingalpha.com/symbol/BBP' title='BioShares Biotechnology Products ETF'>BBP</a>, <a href='https://seekingalpha.com/symbol/LABD' title='Direxion Daily S&P Biotech Bear 3x Shares ETF'>LABD</a>, <a href='https://seekingalpha.com/symbol/UBIO' title='ProShares UltraPro NASDAQ Biotechnology ETF'>UBIO</a>, <a href='https://seekingalpha.com/symbol/ZBIO' title='ProShares UltraPro Short NASDAQ Biotechnology ETF'>ZBIO</a>, <a href='https://seekingalpha.com/symbol/LABS' title='Direxion Daily S&P Biotech Bear 1X Shares ETF'>LABS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248254\" data-linked=\"Animal spirits continue in biotech\" data-tweet=\"$KPTI $KPTI $IMGN - Animal spirits continue in biotech https://seekingalpha.com/news/3248254-animal-spirits-continue-in-biotech?source=tweet\" data-url=\"https://seekingalpha.com/news/3248254-animal-spirits-continue-in-biotech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248251\" data-ts=\"1488478339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETFC\" target=\"_blank\">ETFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248251-online-brokers-decline-after-e-trade-joins-rate-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Online brokers decline after E*Trade joins rate cuts</a></h4><ul><li>While E*Trade's (<a href='https://seekingalpha.com/symbol/ETFC' title='E*TRADE Financial Corporation'>ETFC</a> <font color='red'>-2.3%</font>) move to slash commissions was expected given the big cuts from competitors earlier this week, what was at least somewhat surprising was the change to its active trading tier, <a href=\"http://blogs.barrons.com/focusonfunds/2017/03/02/etrade-cuts-fees-too-active-traders-win-this-round/?mod=BOL_hp_blog_fof\" target=\"_blank\">says Wells Fargo's Chris Harris</a>.</li><li>Just 30 trades per quarter are necessary for eligibility vs. 150 previously.</li><li>Ahead of the announcement, Harris had already reduced EPS estimates for E*Trade by 8-10%, and now he's cutting another two cents off to $1.83 for 2017. 2018 expectations are reaffirmed at $1.97, as is the price target range of $36-$40 (current is just under $36).</li><li>Harris: \"While the price cutting moves that have occurred in recent weeks are a negative for e-broker fundamentals and the stocks, we are optimistic that there won&rsquo;t be further wholesale pricing reductions at this juncture (as there are no clear winners from these actions).\"</li><li>Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='red'>-1.4%</font>), Ameritrade (<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a> <font color='red'>-3.1%</font>), Interactive Brokers (<a href='https://seekingalpha.com/symbol/IBKR' title='Interactive Brokers Group, Inc.'>IBKR</a> <font color='red'>-1.5%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248087-e-trade-joins-competitors-commission-cut\" target=\"_blank\">E*Trade joins competitors with commission cut</a> (March 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248251\" data-linked=\"Online brokers decline after E*Trade joins rate cuts\" data-tweet=\"$ETFC $ETFC $SCHW - Online brokers decline after E*Trade joins rate cuts https://seekingalpha.com/news/3248251-online-brokers-decline-after-e-trade-joins-rate-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3248251-online-brokers-decline-after-e-trade-joins-rate-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248250\" data-ts=\"1488478013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIRM\" target=\"_blank\">AIRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248250-bloomberg-air-methods-in-play\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Air Methods in play</a></h4><ul><li>Air Methods (<a href='https://seekingalpha.com/symbol/AIRM' title='Air Methods Corporation'>AIRM</a> <font color='green'>+11.3%</font>) spikes on reports the company is receiving takeover bids.</li><li>Bloomberg News reports that KKR is in the mix.</li><li>Shares of Air Methods are at a 52-week high.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248250\" data-linked=\"Bloomberg: Air Methods in play\" data-tweet=\"$AIRM - Bloomberg: Air Methods in play https://seekingalpha.com/news/3248250-bloomberg-air-methods-in-play?source=tweet\" data-url=\"https://seekingalpha.com/news/3248250-bloomberg-air-methods-in-play\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248248\" data-ts=\"1488477902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248248-micron-technologyplus-1_85-q2-2017-expected-above-high-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology +1.85%; Q2 2017 expected at or above high-end of guidance</a></h4><ul><li><strong>Preliminary Q2 2017 results</strong>&nbsp;&ndash; revenue $4.65B (+/- $50M) [vs. $4.35B-$4.7B expected prior, <a href=\"https://finance.yahoo.com/quote/MU/analysts?p=MU\" target=\"_blank\">$4.55B consensus</a>], EPS $0.86 (+/- a few cents) [vs. $0.58-$0.68 prior, $0.66 consensus], gross margin 37.5% (+/- 0.5%) [vs. 31%-34% prior]</li><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) attributes mix, cost improvements and pricing to the affirmative preannouncement, while noting overall demand health remains, and into Q3 2017, so do positive operational and market momentum.</li><li>Micron's formal reporting is <a href=\"http://investors.micron.com/releasedetail.cfm?ReleaseID=1014296\" target=\"_blank\">scheduled for March 23</a>.</li><li><a href=\"https://seekingalpha.com/filing/3440422\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248248\" data-linked=\"Micron Technology +1.85%; Q2 2017 expected at or above high-end of guidance\" data-tweet=\"$MU - Micron Technology +1.85%; Q2 2017 expected at or above high-end of guidance https://seekingalpha.com/news/3248248-micron-technologyplus-1_85-q2-2017-expected-above-high-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3248248-micron-technologyplus-1_85-q2-2017-expected-above-high-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248241\" data-ts=\"1488477619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248241-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> AHP <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ARES' title='Ares Management Corporation'>ARES</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NMIH' title='NMI Holdings, Inc.'>NMIH</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248241\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$PMTS $BHR $ARES - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3248241-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3248241-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248244\" data-ts=\"1488477445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248244-slowing-t-mobile-cuts-deutsche-telekom-growth-forecast-merger-likely\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Slowing T-Mobile cuts Deutsche Telekom growth forecast; merger more likely?</a></h4><ul>   <li>With expectations for slowing growth from its T-Mobile (<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='green'>+0.6%</font>) arm, Deutsche Telekom (<a href='https://seekingalpha.com/symbol/DTEGY' title='Deutsche Telekom AG ADR'>OTCQX:DTEGY</a> <font color='red'>-1.5%</font>) is saying its <a href=\"http://www.reuters.com/article/us-deutsche-telekom-results-consolidatio-idUSKBN1691B8\" target=\"_blank\">core profit growth would cut in half</a> this year.</li>    <li>As far as DT is concerned, that only builds the case for a U.S. merger that recently has the attention of Sprint (<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a> <font color='red'>-0.8%</font>) owner SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a> <font color='red'>-1.9%</font>). That company is reportedly <a href=\"https://seekingalpha.com/news/3244519-sprint-t-mobile-spike-report-softbank-pursue-carrier-merger\" target=\"_blank\">willing to give up control</a> of Sprint to DT in order to seal the deal.</li>    <li>With both parties seeming willing, it may come down to logistics and regulators. \"Are we rather seller or buyer? It always depends on the quality of the possibilities,\" says Deutsche Telekom CEO Tim Hoettges. \"I don't prejudge. We do everything from the point of view of value creation.\"</li>    <li>DT's EBITDA is expected to rise just under 4% to about &euro;22.2B in 2017. T-Mobile US saw its EBITDA grow 29% last year and that's expected to slow to 7% this year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248244\" data-linked=\"Slowing T-Mobile cuts Deutsche Telekom growth forecast; merger more likely?\" data-tweet=\"$TMUS $TMUS $DTEGY - Slowing T-Mobile cuts Deutsche Telekom growth forecast; merger more likely? https://seekingalpha.com/news/3248244-slowing-t-mobile-cuts-deutsche-telekom-growth-forecast-merger-likely?source=tweet\" data-url=\"https://seekingalpha.com/news/3248244-slowing-t-mobile-cuts-deutsche-telekom-growth-forecast-merger-likely\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248238\" data-ts=\"1488476868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248238-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='green'>+48%</font>. <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/NVGS' title='Navigator Holdings Ltd.'>NVGS</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/AMRC' title='Ameresco, Inc.'>AMRC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-46%</font>. <a href='https://seekingalpha.com/symbol/CALI' title='China Auto Logistics Inc.'>OTC:CALI</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/RGCO' title='RGC Resources Inc.'>RGCO</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/OME' title='Omega Protein Corporation'>OME</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='red'>-16%</font>. SKLN <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VEC' title='Vectrus'>VEC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TIK' title='Tel-Instrument Electronics Corp'>TIK</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248238\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SNAP $AUPH $KPTI - Midday Gainers / Losers https://seekingalpha.com/news/3248238-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3248238-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248223\" data-ts=\"1488475678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248223-activist-investor-venbio-rejects-immunomedics-latest-settlement-proposal-in-tussle-over\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist investor venBio rejects Immunomedics&#39; latest settlement proposal in tussle over control; shares up 3%</a></h4><ul><li>Immunomedics (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+2.9%</font>) is up on slightly higher volume on the heels of its <a href=\"https://seekingalpha.com/pr/16759808-immunomedics-outlines-revised-settlement-offer-rejected-venbio-announces-actions-best\" target=\"_blank\">announcement </a>that activist shareholder venBio has rejected its revised settlement proposal ahead of tomorrow's annual meeting.</li><li>Management offered to appoint all four venBio-backed board nominees, to continue the search for a new CEO and Vice Chairman Jason Aryeh will step down.</li><li>Apparently, venBio remains unmollified with the overtures. It will attempt to wrest control of the company tomorrow so it can stop the Seattle Genetics (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color='green'>+0.7%</font>) deal which it says \"gives away the crown jewel\" IMMU-132.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3242669-activist-investor-venbio-takes-issue-immunomedics-deal-seattle-genetics\" target=\"_blank\">Activist investor venBio takes issue with Immunomedics' deal with Seattle Genetics</a> (Feb. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248223\" data-linked=\"Activist investor venBio rejects Immunomedics&#39; latest settlement proposal in tussle over control; shares up 3%\" data-tweet=\"$IMMU $IMMU $SGEN - Activist investor venBio rejects Immunomedics&#39; latest settlement proposal in tussle over control; shares up 3% https://seekingalpha.com/news/3248223-activist-investor-venbio-rejects-immunomedics-latest-settlement-proposal-in-tussle-over?source=tweet\" data-url=\"https://seekingalpha.com/news/3248223-activist-investor-venbio-rejects-immunomedics-latest-settlement-proposal-in-tussle-over\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248224\" data-ts=\"1488475655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAT\" target=\"_blank\">CAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248224-caterpillar-sinks-4_8-federal-officials-search-hq-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caterpillar sinks 4.8% as federal officials search HQ (updated)</a></h4><ul>   <li>Caterpillar (NYSE:<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a>) shares are <font color='red'>4.8% lower</font> as federal officials <a href=\"http://www.pjstar.com/news/20170302/law-enforcement-officials-searching-caterpillar-offices\" target=\"_blank\">search the company's headquarters</a> and other area facilities, the company confirms.</li>    <li>It's not yet clear which agency is searching, or for what. But \"Caterpillar is cooperating,\" the company says.</li>    <li>An employee source says that some employees have been directed to the cafeteria and told to remain there.</li><li>Some officials entering the building had jackets with IRS logos, while others appeared to be from the FDIC, the <em>Peoria Journal Star</em> reports. Still others seemed to be tied to police from the Commerce Dept.</li><li><strong>Updated 1:18 p.m.:</strong> NBC&nbsp;station WEEK&nbsp;reports that the agents are seeking tax documentation and have asked tax employees to leave the building.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248224\" data-linked=\"Caterpillar sinks 4.8% as federal officials search HQ (updated)\" data-tweet=\"$CAT - Caterpillar sinks 4.8% as federal officials search HQ (updated) https://seekingalpha.com/news/3248224-caterpillar-sinks-4_8-federal-officials-search-hq-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3248224-caterpillar-sinks-4_8-federal-officials-search-hq-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248222\" data-ts=\"1488474614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248222-iron-ore-prices-may-snap-back-toward-fundamentals-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iron ore prices may snap back toward fundamentals, analyst says</a></h4><ul>     <li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-5.8%</font>), Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-2.5%</font>) and BHP&nbsp;Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-1%</font>) are lower following a report from Axiom Capital's Gordon Johnson warning iron ore investors to <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9119757/gordon-johnson-an-imminent-end-to-an-epic-restock-sugges\" target=\"_blank\">prepare for a flood of new supply</a> to come online in the next several years.</li>     <li>Johnson argues that the Chinese steel mill restocking cycle, the largest in more than six years, has contributed to the rapid rise in iron ore prices, but that steel inventory is peaking and iron ore prices will soon reflect underlying market fundamentals.</li>     <li>Johnson forecasts excess seaborne supply of iron ore will jump to 269M tons by 2020 from an estimated 37M tons in 2016, and sees iron ore prices of $60/ton in 2017 and $40/ton in 2018 from ~$91.30 currently.</li>     <li>Also, Reuters reports that surging iron ore prices may prompt Chinese producers to <a href=\"http://www.reuters.com/article/us-china-ironore-idUSKBN16911Q\" target=\"_blank\">reopen shuttered mines</a>, potentially tightening the market.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248222\" data-linked=\"Iron ore prices may snap back toward fundamentals, analyst says\" data-tweet=\"$VALE $VALE $RIO - Iron ore prices may snap back toward fundamentals, analyst says https://seekingalpha.com/news/3248222-iron-ore-prices-may-snap-back-toward-fundamentals-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3248222-iron-ore-prices-may-snap-back-toward-fundamentals-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248220\" data-ts=\"1488474074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248220-consumer-top-5-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top 5 Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International Inc.'>SUP</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OME' title='Omega Protein Corporation'>OME</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/GEF' title='Greif, Inc.'>GEF</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/VGR' title='Vector Group Ltd.'>VGR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RELV' title='Reliv&#39; International, Inc.'>RELV</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248220\" data-linked=\"Consumer - Top 5 Gainers / Losers as of 12:00 pm\" data-tweet=\"$MNST $SUP $FFHL - Consumer - Top 5 Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3248220-consumer-top-5-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3248220-consumer-top-5-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248217\" data-ts=\"1488473798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248217-advanced-micro-devicesminus-4_4-amid-ryzen-7-release\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advanced Micro Devices -4.4% amid Ryzen 7 release</a></h4><ul><li>Long-awaited <a href=\"https://seekingalpha.com/pr/16759616-amd-ryzen-tm-7-desktop-processors-featuring-record-breaking-overclocking-performance\" target=\"_blank\">availability</a> of Advanced Micro Devices' (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) Ryzen 7 processors&nbsp;materializes today with three 8-core Ryzen 7 models now on the market. Ryzen 5 and Ryzen 3 processors are planned for launches later in the year.</li><li>While some early&nbsp;<a href=\"https://arstechnica.com/gadgets/2017/03/amd-ryzen-review/\" target=\"_blank\">in-depth reviews</a>&nbsp;suggests sound value for price, and strength for the CPUs among workstations, certain shortcomings in gaming capability are observed, prospectively weighing in part on initial reception.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248217\" data-linked=\"Advanced Micro Devices -4.4% amid Ryzen 7 release\" data-tweet=\"$AMD - Advanced Micro Devices -4.4% amid Ryzen 7 release https://seekingalpha.com/news/3248217-advanced-micro-devicesminus-4_4-amid-ryzen-7-release?source=tweet\" data-url=\"https://seekingalpha.com/news/3248217-advanced-micro-devicesminus-4_4-amid-ryzen-7-release\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>285&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248216\" data-ts=\"1488473345\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPW\" target=\"_blank\">MPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248216-medical-properties-trustminus-4-adeptus-worry-escalates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medical Properties Trust -4% as Adeptus worry escalates</a></h4><ul><li>Medical Properties Trust (<a href='https://seekingalpha.com/symbol/MPW' title='Medical Properties Trust, Inc.'>MPW</a> <font color='red'>-4.1%</font>) tenant, emergency room operator Adeptus Health (<a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-45.7%</font>), warns of \"substantial doubt\" on its ability to continue as a going concern.</li><li>Noting a meeting with MPW CFO Steven Hammer, Mitsubishi's Karin Ford says ADPT is current on rent through February, and MPW has letter of credit for four months' rent and may be able to find a replacement operator.</li><li>Source: Bloomberg</li><li>Adeptus accounts for 7% of total MPW revenue according to <a href=\"https://seekingalpha.com/filing/3438983\" target=\"_blank\">the 10-K</a> filed yesterday.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248216\" data-linked=\"Medical Properties Trust -4% as Adeptus worry escalates\" data-tweet=\"$MPW $MPW $ADPT-RETIRED - Medical Properties Trust -4% as Adeptus worry escalates https://seekingalpha.com/news/3248216-medical-properties-trustminus-4-adeptus-worry-escalates?source=tweet\" data-url=\"https://seekingalpha.com/news/3248216-medical-properties-trustminus-4-adeptus-worry-escalates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248208\" data-ts=\"1488472585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEIX\" target=\"_blank\">PEIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248208-pacific-ethanolplus-3-following-q4-earnings-beat-strong-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Ethanol +3% following Q4 earnings beat, strong outlook</a></h4><ul>     <li>Pacific Ethanol (<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='green'>+3.2%</font>) powers higher after <a href=\"https://seekingalpha.com/news/3247854-pacific-ethanol-beats-0_09-beats-revenue\" target=\"_blank\">Q4 earnings</a> easily topped expectations and revenues rose 17% Y/Y, due to increases in gallons sold from both production and third party sales as well as a higher average ethanol sales price per gallon.</li>     <li>For FY 2016, PEIX says net sales rose 36%&nbsp;Y/Y to $1.19B on a record 924.5M total gallons sold.</li>     <li>PEIX says the outlook for 2017 is \"encouraging,\" and expects ethanol demand to remain strong, supported by healthy exports and higher gasoline demand.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248208\" data-linked=\"Pacific Ethanol +3% following Q4 earnings beat, strong outlook\" data-tweet=\"$PEIX - Pacific Ethanol +3% following Q4 earnings beat, strong outlook https://seekingalpha.com/news/3248208-pacific-ethanolplus-3-following-q4-earnings-beat-strong-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3248208-pacific-ethanolplus-3-following-q4-earnings-beat-strong-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248202\" data-ts=\"1488471789\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSI\" target=\"_blank\">SSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248202-volatile-trading-on-stage-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatile trading on Stage Stores</a></h4><ul> <li>Stage Stores (<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-13.1%</font>) is trading with huge volatility amid some confusing news emanating from a <a href=\"https://seekingalpha.com/filing/3440090\" target=\"_blank\">SEC filing</a>.</li> <li>While HMA Acquisition disclosed that it's prepared to make an offer of $4.60 per share for Stage Stores, some digging around by Bloomberg couldn't verify HMA's existence.</li> <li>Stage Stores was down as much as 31% in the premarket session after earnings arrived.</li><li>Volume on SSI is already 4X normal activity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248001-stage-stores-misses-0_07-beats-revenue\" target=\"_blank\">Stage Stores misses by $0.07, beats on revenue</a> (March 2)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248063-stage-stores-lower-post-q4-results\" target=\"_blank\">Stage Stores lower post Q4 results</a> (March 2)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3248202\" data-linked=\"Volatile trading on Stage Stores\" data-tweet=\"$SSI - Volatile trading on Stage Stores https://seekingalpha.com/news/3248202-volatile-trading-on-stage-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3248202-volatile-trading-on-stage-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248196\" data-ts=\"1488471233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248196-nektar-q4-top-line-down-5-cash-consumption-up-60-in-2016-shares-ahead-19-on-pipeline-progress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar Q4 top line down 5%; cash consumption up 60% in 2016; shares ahead 19% on pipeline progress</a></h4><ul><li>Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+18.6%</font>)<a href=\"https://seekingalpha.com/pr/16758614-nektar-therapeutics-reports-fourth-quarter-year-end-2016-financial-results\" target=\"_blank\"> Q4 results</a> ($M): Total Revenues: 37.5 (-4.8%); Product Sales: 13.7 (-2.1%).</li><li>Net Loss: (42.2) (+22.0%); Loss/Share: (0.28) (+30.0%); cash flow ops (full year): (117.0) (-60.1%).</li><li>Shares are rallying on the company's pipeline progress. Its <a href=\"https://clinicaltrials.gov/ct2/show/NCT02983045?term=nktr-214&amp;rank=2\" target=\"_blank\">Phase 1/2 study</a> of NKTR-214 with Bristol-Myers' Opdivo in solid tumors is \"proceeding nicely\" with interim data expected mid-year. Later this month, Phase 3 data will be available for NKTR-181 in patients with chronic low back pain. A first-in-human trial assessing immune disorder candidate NKTR-358 has been initiated.</li><li>Shares are up on triple normal volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248196\" data-linked=\"Nektar Q4 top line down 5%; cash consumption up 60% in 2016; shares ahead 19% on pipeline progress\" data-tweet=\"$NKTR - Nektar Q4 top line down 5%; cash consumption up 60% in 2016; shares ahead 19% on pipeline progress https://seekingalpha.com/news/3248196-nektar-q4-top-line-down-5-cash-consumption-up-60-in-2016-shares-ahead-19-on-pipeline-progress?source=tweet\" data-url=\"https://seekingalpha.com/news/3248196-nektar-q4-top-line-down-5-cash-consumption-up-60-in-2016-shares-ahead-19-on-pipeline-progress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248162\" data-ts=\"1488470523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248162-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-45%</font>. <a href='https://seekingalpha.com/symbol/ANIP' title='ANI Pharmaceuticals, Inc.'>ANIP</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248162\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$AUPH $KPTI $NKTR - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3248162-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3248162-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248193\" data-ts=\"1488470321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KITE\" target=\"_blank\">KITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248193-kite-prices-equity-offering-shares-off-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kite prices equity offering; shares off 5%</a></h4><ul><li>Kite Pharma (<a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='red'>-5%</font>) is down on more than triple normal volume in response to the <a href=\"https://seekingalpha.com/pr/16759688-kite-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 4.75M shares of common stock at $75 per share. Underwriters over-allotment is an additional 712.5K shares. The offering is pursuant to a shelf registration filed on December 8, 2015.</li><li>Yesterday's close was $79.62.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248193\" data-linked=\"Kite prices equity offering; shares off 5%\" data-tweet=\"$KITE - Kite prices equity offering; shares off 5% https://seekingalpha.com/news/3248193-kite-prices-equity-offering-shares-off-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3248193-kite-prices-equity-offering-shares-off-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248188\" data-ts=\"1488469528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRML\" target=\"_blank\">VRML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248188-vermillions-aspira-labs-inks-deal-michigan-bsbc-for-ovarian-cancer-test-shares-ahead-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vermillion&#39;s ASPiRA LABs inks deal with Michigan BSBC for ovarian cancer test; shares ahead 10%</a></h4><ul><li>Thinly traded micro cap Vermillion (<a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a> <font color='green'>+10.2%</font>) heads north on more than a 7x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16758559-aspira-labs-announces-contracted-network-agreement-blue-cross-blue-shield-michigan-ova1\" target=\"_blank\">announcement </a>that subsidiary ASPiRA LABs has signed a contract with Blue Cross Blue Shield of Michigan for its ovarian cancer &#40;OC&#41;&nbsp;risk assessment test called OVA1.</li><li><a href=\"http://vermillion.com/our-products/\" target=\"_blank\">OVA1 </a>evaluates the levels of five ovarian cancer-associated biomarkers in the blood and combines the levels into a single OC risk score.</li><li>BCBS of Michigan serves over 6M beneficiaries. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248188\" data-linked=\"Vermillion&#39;s ASPiRA LABs inks deal with Michigan BSBC for ovarian cancer test; shares ahead 10%\" data-tweet=\"$VRML - Vermillion&#39;s ASPiRA LABs inks deal with Michigan BSBC for ovarian cancer test; shares ahead 10% https://seekingalpha.com/news/3248188-vermillions-aspira-labs-inks-deal-michigan-bsbc-for-ovarian-cancer-test-shares-ahead-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3248188-vermillions-aspira-labs-inks-deal-michigan-bsbc-for-ovarian-cancer-test-shares-ahead-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248189\" data-ts=\"1488469355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTK\" target=\"_blank\">FTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248189-flotekplus-2-unveils-double-digit-price-increase-amid-rising-activity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flotek +2% as it unveils double-digit price increase amid rising activity</a></h4><ul>     <li>Flotek Industries (<a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a> <font color='green'>+1.1%</font>) powers higher as it presents an <a href=\"http://www.flotekind.com/media/k2/attachments/FTKZInvestorZDeckZ2.27_REVISEDZ6pm.pdf\" target=\"_blank\">upbeat outlook</a> at the EnerCom oil and gas conference.</li><li>FTK says it has initiated a double-digit price increase, effective this quarter, as activity levels rise and it anticipates continued improvement in completion activity.</li><li>FTK also says it is enjoying strong demand in energy chemistry, and is focused on delivering improved margins through strategic pricing increases and process efficiency during 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248189\" data-linked=\"Flotek +2% as it unveils double-digit price increase amid rising activity\" data-tweet=\"$FTK - Flotek +2% as it unveils double-digit price increase amid rising activity https://seekingalpha.com/news/3248189-flotekplus-2-unveils-double-digit-price-increase-amid-rising-activity?source=tweet\" data-url=\"https://seekingalpha.com/news/3248189-flotekplus-2-unveils-double-digit-price-increase-amid-rising-activity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248186\" data-ts=\"1488468993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GES\" target=\"_blank\">GES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248186-relief-rally-for-retail-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Relief rally for retail stocks</a></h4><ul> <li>Retail stocks are outperforming on the day as the sector recovers a bit from the Target bombshell earnings cut earlier this week and as border tax fears ease up a bit. The latest word from D.C. is that border tax legislation may be pushed into 2018.</li> <li>The S&amp;P Retail ETF&nbsp;(NYSEARCA:<a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>) is <font color='green'>up 1.12%</font> on a day that all three major indexes are in negative territory.</li> <li>Notable retail gainers include Guess (<a href='https://seekingalpha.com/symbol/GES' title='Guess? Inc.'>GES</a> <font color='green'>+4%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='green'>+4.1%</font>), Ascena Retail (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+5.2%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='green'>+4.8%</font>), Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='green'>+5.7%</font>), Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='green'>+3.5%</font>), Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a> <font color='green'>+4.4%</font>) and Dollar Tree (<a href='https://seekingalpha.com/symbol/DLTR' title='Dollar Tree, Inc.'>DLTR</a> <font color='green'>+3.2%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3248186\" data-linked=\"Relief rally for retail stocks\" data-tweet=\"$GES $XRT $GES - Relief rally for retail stocks https://seekingalpha.com/news/3248186-relief-rally-for-retail-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3248186-relief-rally-for-retail-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248185\" data-ts=\"1488468930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRE\" target=\"_blank\">DRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248185-duke-realty-reportedly-exploring-asset-sale-sharesplus-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Duke Realty reportedly exploring asset sale; shares +1%</a></h4><ul><li><a href=\"https://www.streetinsider.com/Mergers+and+Acquisitions/Duke+Realty+%28DRE%29+explores+sale+of+Medical+Office+portfolio+worth+as+much+as+%243B+-+Reuters/12620935.html\" target=\"_blank\">According to Reuters</a>, Duke Realty (<a href='https://seekingalpha.com/symbol/DRE' title='Duke Realty Corp.'>DRE</a> <font color='green'>+1%</font>) is muling the sale of its medical office portfolio, which could be worth as much as $3B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248185\" data-linked=\"Duke Realty reportedly exploring asset sale; shares +1%\" data-tweet=\"$DRE - Duke Realty reportedly exploring asset sale; shares +1% https://seekingalpha.com/news/3248185-duke-realty-reportedly-exploring-asset-sale-sharesplus-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3248185-duke-realty-reportedly-exploring-asset-sale-sharesplus-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248183\" data-ts=\"1488468892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248183-coherus-humira-biosimilar-candidate-successful-in-bioequivalence-study-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherus&#39; Humira biosimilar candidate successful in bioequivalence study; shares ahead 4%</a></h4><ul><li>Coherus BioSciences (<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+4.2%</font>) perks up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16759458-coherus-announces-chsminus-1420-pharmacokinetic-clinical-bioequivalence-study-meets-primary\" target=\"_blank\">announcement</a> that an early-stage study assessing Humira (adalimumab) biosimilar candidate CHS-1420 met its primary endpoint of demonstrating clinical pharmacokinetic bioequivalence on all endpoints. Also, there were no safety signals observed between the two products.</li><li>The study, called CHS-1420-03, evaluated a single 40 mg dose in healthy subjects. It is the second successful PK trial. More are on tap this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248183\" data-linked=\"Coherus&#39; Humira biosimilar candidate successful in bioequivalence study; shares ahead 4%\" data-tweet=\"$CHRS - Coherus&#39; Humira biosimilar candidate successful in bioequivalence study; shares ahead 4% https://seekingalpha.com/news/3248183-coherus-humira-biosimilar-candidate-successful-in-bioequivalence-study-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3248183-coherus-humira-biosimilar-candidate-successful-in-bioequivalence-study-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248184\" data-ts=\"1488468632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248184-natural-gas-futures-fall-after-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas futures fall further after inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+7&nbsp;Bcf</strong> vs. -4 Bcf consensus, -89 Bcf last week.</li>     <li>Futures&nbsp;<font color='red'>-0.75%</font>&nbsp;to $2.778.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3248184\" data-linked=\"Natural gas futures fall further after inventory data\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas futures fall further after inventory data https://seekingalpha.com/news/3248184-natural-gas-futures-fall-after-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3248184-natural-gas-futures-fall-after-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248181\" data-ts=\"1488468472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPT\" target=\"_blank\">BPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248181-bp-prudhoe-bayminus-10-projects-royalty-payments-to-cease-after-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BP Prudhoe Bay -10%, projects royalty payments to cease after 2018</a></h4><ul><li>BP Prudhoe Bay Royalty (<a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a> <font color='red'>-9.6%</font>) sinks ~10% in early trading after disclosing that its royalty payments are projected to end after 2018.</li><li>In its 2016 <a href=\"https://seekingalpha.com/filing/3438369\" target=\"_blank\">Form 10-K</a>, BPT estimates that royalty payments to the trust will continue through the year 2018 but would be zero in the following year, and no proved reserves currently are attributed to the trust after that date; calculations were based on the 2016 average WTI price of $42.75/bbl.</li><li>In the prior year's disclosure, BPT projected royalty payments, using a 2015 WTI price of $50.28/bbl, would cease after 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248181\" data-linked=\"BP Prudhoe Bay -10%, projects royalty payments to cease after 2018\" data-tweet=\"$BPT - BP Prudhoe Bay -10%, projects royalty payments to cease after 2018 https://seekingalpha.com/news/3248181-bp-prudhoe-bayminus-10-projects-royalty-payments-to-cease-after-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3248181-bp-prudhoe-bayminus-10-projects-royalty-payments-to-cease-after-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248177\" data-ts=\"1488468113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248177-broadcomplus-2_3-analysts-laud-first-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom +2.3% as analysts laud first quarter</a></h4><ul>   <li>Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>) is <font color='green'>up 2.3%</font> this morning after <a href=\"https://seekingalpha.com/news/3247830-broadcom-plus-3_7-percent-q1-beats-top-bottom-lines\" target=\"_blank\">beating some already high expectations</a> in its first quarter and providing solid guidance for the coming quarter.</li>    <li>Even as the Street gets less conservative, there's still a lot of headroom and the stock has a clear path to $240-$250 (vs. $220 today), Cowen says in reiterating an Outperform rating. The company should be able to appeal to income investors as it shifts to higher capital returns, analyst Timothy Arcuri notes.</li>    <li>It was a \"wonderful quarter,\" says Susquehanna's Christopher Rolland, who's raised the firm's price target to $250 from $220 (implying 13.6% upside). The stock is a \"must-own large cap in semis,\" he says, noting wireless guidance on the call was better than expected.</li>    <li>Morgan Stanley reiterated its Overweight rating and raised price target to $245 from $240, calling it a \"core investment holding.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248177\" data-linked=\"Broadcom +2.3% as analysts laud first quarter\" data-tweet=\"$AVGO - Broadcom +2.3% as analysts laud first quarter https://seekingalpha.com/news/3248177-broadcomplus-2_3-analysts-laud-first-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3248177-broadcomplus-2_3-analysts-laud-first-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248175\" data-ts=\"1488467940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248175-abercrombie-fitchplus-13-despite-earnings-whiff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abercrombie &amp; Fitch +13% despite earnings whiff</a></h4><ul> <li>Though Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+12.7%</font>) missed estimates across the board (revenue, EPS, comparable sales) - shares are flying higher off some green shoots of improvement seen for Hollister.</li> <li>Retail analyst Stacy Widlitz <a href=\"https://twitter.com/StaceyRetail/status/837295178742382592\" target=\"_blank\">ran the numbers</a> to find that Abercrombie's comparable sales on a three-year look are down 24%.</li> <li>Shares of A&amp;F trade at their highest level of the year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248053-abercrombie-and-fitch-misses-0_04-misses-revenue\" target=\"_blank\">Abercrombie &amp; Fitch misses by $0.04, misses on revenue</a> (March 2)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3248175\" data-linked=\"Abercrombie &amp; Fitch +13% despite earnings whiff\" data-tweet=\"$ANF - Abercrombie &amp; Fitch +13% despite earnings whiff https://seekingalpha.com/news/3248175-abercrombie-fitchplus-13-despite-earnings-whiff?source=tweet\" data-url=\"https://seekingalpha.com/news/3248175-abercrombie-fitchplus-13-despite-earnings-whiff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248174\" data-ts=\"1488467569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNFTF\" target=\"_blank\">GNFTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248174-genfit-up-23-on-rumored-novartis-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genfit up 23% on rumored Novartis interest</a></h4><ul><li>Thinly traded micro cap Genfit (<a href='https://seekingalpha.com/symbol/GNFTF' title='Genfit'>OTCPK:GNFTF</a> <font color='green'>+22.7%</font>) jumps&nbsp;in early trading stoked by rumors that Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='red'>-1.1%</font>) is eyeing the company according to a source close to the matter.</li><li>Genfit's lead product candidate is Fast Track-tagged Elafibranor (GFT505) for the treatment of non-alcoholic steatohepatitis &#40;NASH&#41;.</li><li>Source: StreetInsider</li><li>Previously: <a href=\"https://seekingalpha.com/news/2931356-pivotal-late-stage-study-genfits-nash-candidate-commence-quarter\" target=\"_blank\">Pivotal late-stage study of GENFIT's NASH candidate to commence this quarter</a> (Nov. 16, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3248174\" data-linked=\"Genfit up 23% on rumored Novartis interest\" data-tweet=\"$GNFTF $GNFTF $NVS - Genfit up 23% on rumored Novartis interest https://seekingalpha.com/news/3248174-genfit-up-23-on-rumored-novartis-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3248174-genfit-up-23-on-rumored-novartis-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248163\" data-ts=\"1488466594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248163-leerink-likes-sarepta-sees-42-upside-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leerink likes Sarepta, sees 42% upside; shares up 10%</a></h4><ul><li>Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+10%</font>) jumps out of the gate, albeit on light volume, on the heels of an upgrade by Leerink Swann to Outperform with a $47 price target (from $27).</li><li>Analyst Joseph Schwartz says the stock has \"fully consolidated\" and reflects \"reasonable expectations\" for the launch of Exondys 51. Guidance of more that $80M for 2017 is \"achievable\" considering the steady increase in start forms after initial bolus.</li><li>Projects 117 patients on Exondys 51 this year, representing almost 47% of the 250 start forms received. Assuming no increase in start forms, the conversion rate will to increase to 65% in order for the company to hit $80M.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3248163\" data-linked=\"Leerink likes Sarepta, sees 42% upside; shares up 10%\" data-tweet=\"$SRPT - Leerink likes Sarepta, sees 42% upside; shares up 10% https://seekingalpha.com/news/3248163-leerink-likes-sarepta-sees-42-upside-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3248163-leerink-likes-sarepta-sees-42-upside-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248165\" data-ts=\"1488466415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRC\" target=\"_blank\">AMRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248165-ameresco-soars-after-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ameresco soars after Q4 beat</a></h4><ul><li>Net income of $3.5M, or $0.08 per diluted share vs. $4.2M, or $0.09 per diluted share in the same quarter a year ago. Adjusted EBITDA of $56.2M, up 23%.</li><li>Total project backlog +11% to $1.5B; Contracted backlog +37% to $534.1M; Assets in development +35% to $228.3M.</li><li>Authorized a share repurchase increase to $15M, up from $10M, of Ameresco (<a href='https://seekingalpha.com/symbol/AMRC' title='Ameresco, Inc.'>AMRC</a> <font color='green'>+18.3%</font>) Class A common stock.</li><li>Guidance for 2017: Net income per diluted share of $0.37-$0.43; Revenue of $665M-$700M; Adjusted EBITDA of $60M-$65M.</li><li><a href=\"https://seekingalpha.com/news/3247987-ameresco-beats-0_04-beats-revenue\" target=\"_blank\">Q4 results</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3248165\" data-linked=\"Ameresco soars after Q4 beat\" data-tweet=\"$AMRC - Ameresco soars after Q4 beat https://seekingalpha.com/news/3248165-ameresco-soars-after-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3248165-ameresco-soars-after-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248161\" data-ts=\"1488465878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKRX\" target=\"_blank\">AKRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248161-fda-oks-akorns-ephedrine-sulfate-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Akorn&#39;s ephedrine sulfate; shares ahead 4%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16759400-akorn-receives-fda-approval-ephedrine-sulfate-injection-usp\" target=\"_blank\">approves </a>Akorn's (<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color='green'>+4.3%</font>) <a href=\"https://www.drugs.com/pro/ephedrine-sulphate-injection.html\" target=\"_blank\">ephedrine sulfate injection</a>, USP 50 mg/mL in a 1 mL single-dose ampule for the treatment of clinically important hypotension in an anesthesia setting. The size of the U.S market is ~$180M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248161\" data-linked=\"FDA OKs Akorn&#39;s ephedrine sulfate; shares ahead 4%\" data-tweet=\"$AKRX - FDA OKs Akorn&#39;s ephedrine sulfate; shares ahead 4% https://seekingalpha.com/news/3248161-fda-oks-akorns-ephedrine-sulfate-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3248161-fda-oks-akorns-ephedrine-sulfate-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248159\" data-ts=\"1488465382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARES\" target=\"_blank\">ARES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248159-ares-management-down-10-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ares Management down 10% after share sale</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16759504-ares-management-l-p-announces-pricing-secondary-offering-common-units\" target=\"_blank\">The 7.5M share sale</a> was for strategic investor Abu Dhabi, and it priced at the midpoint of last night's reported range of $19.50-$20.50. The underwriters have a greenshoe option for another 1.125M shares at that price.</li><li><a href='https://seekingalpha.com/symbol/ARES' title='Ares Management Corporation'>ARES</a>&nbsp;<font color='red'>-9.8%</font>&nbsp;to $19.85</li></ul><div class=\"tiny-share-widget\" data-id=\"3248159\" data-linked=\"Ares Management down 10% after share sale\" data-tweet=\"$ARES - Ares Management down 10% after share sale https://seekingalpha.com/news/3248159-ares-management-down-10-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3248159-ares-management-down-10-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248153\" data-ts=\"1488464665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHFS\" target=\"_blank\">CHFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248153-sunshine-heart-net-loss-improves-in-q4-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunshine Heart net loss improves in Q4; shares up 5% premarket</a></h4><ul><li>Sunshine Heart (SSH) <a href=\"https://seekingalpha.com/pr/16759192-sunshine-heart-announces-fourth-quarter-2016-financial-results-provides-company-update\" target=\"_blank\">Q4 results</a>: Revenues: $0.7M; Operating Loss: ($3.1M) (+51.6%); Net Loss: ($2.9M) (+56.1%); Loss Per Share: ($4.64) (+57.1%).</li><li><strong>2016 results</strong>: Revenues: $1.3M; Operating Loss: ($15.7M) (+39.6%); Net Loss: ($15.8M) (+40.6%); Loss Per Share: ($27.06) (+38.5%); Quick Assets: $1.3M (-94.4%); CF Ops: ($16.3M) (+29.1%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>5.1%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248153\" data-linked=\"Sunshine Heart net loss improves in Q4; shares up 5% premarket\" data-tweet=\"$CHFS - Sunshine Heart net loss improves in Q4; shares up 5% premarket https://seekingalpha.com/news/3248153-sunshine-heart-net-loss-improves-in-q4-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3248153-sunshine-heart-net-loss-improves-in-q4-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248151\" data-ts=\"1488464514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHR\" target=\"_blank\">BHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248151-ashford-prime-down-7_3-after-equity-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ashford Prime down 7.3% after equity capital raise</a></h4><ul><li>The company priced <a href=\"https://seekingalpha.com/pr/16759503-ashford-prime-prices-public-offering-common-stock\" target=\"_blank\">a 5.75M share secondary</a> at $12.15 each. The underwriters have a greenshoe for another 862.5K shares at that price.</li><li>AHP<font color='red'> -7.3%</font>&nbsp;to $11.96 premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3248151\" data-linked=\"Ashford Prime down 7.3% after equity capital raise\" data-tweet=\"$BHR - Ashford Prime down 7.3% after equity capital raise https://seekingalpha.com/news/3248151-ashford-prime-down-7_3-after-equity-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3248151-ashford-prime-down-7_3-after-equity-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248148\" data-ts=\"1488464341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWH\" target=\"_blank\">CWH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248148-keybanc-calls-near-top-on-camping-world\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc calls a near top on Camping World</a></h4><ul> <li>KeyBanc <a href=\"http://www.benzinga.com/calendar/ratings\" target=\"_blank\">downgrades</a> Camping World (NYSE:<a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a>) to a Sector Weight rating after having the RV stock set at Overweight.</li> <li>\"While CWH has compelling growth prospects, and we believe that there is upside potential to current Street estimates given continued dealer acquisitions and solid industry momentum, we believe that the risk/reward is appropriately balanced with only modest potential upside from current levels,\" writes analyst Scott Hamann.</li> <li>Camping World has been on a stellar run, with shares up 62% since the IPO last October.</li> <li>CWH <font color='red'>-0.38%</font> premarket to $36.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248148\" data-linked=\"KeyBanc calls a near top on Camping World\" data-tweet=\"$CWH - KeyBanc calls a near top on Camping World https://seekingalpha.com/news/3248148-keybanc-calls-near-top-on-camping-world?source=tweet\" data-url=\"https://seekingalpha.com/news/3248148-keybanc-calls-near-top-on-camping-world\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248146\" data-ts=\"1488464262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248146-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+70%</font>. <a href='https://seekingalpha.com/symbol/RADA' title='Rada Electronics Industries Limited'>RADA</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+5%</font>. SSH <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ARES' title='Ares Management Corporation'>ARES</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-8%</font>. AHP <font color='red'>-7%</font>. SKLN <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3248146\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$AUPH $RADA $MNST - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3248146-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3248146-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248143\" data-ts=\"1488463978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOS\" target=\"_blank\">KTOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248143-kratos-defense-to-launch-10_35m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kratos Defense to launch 10.35M-share offering</a></h4><ul><li>Kratos Defense and Security (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a>) <font color='red'>-5.3%</font> premarket after pricing a <a href=\"https://seekingalpha.com/pr/16759613-kratos-defense-and-security-solutions-inc-prices-offering-common-stock\" target=\"_blank\">public offering</a> of  10.35M common shares at $7.25/share for proceeds of  ~$75M, with an underwriters option to purchase up to an additional ~1.55M shares.</li><li>KTOS says it will use the proceeds to reduce debt in order to facilitate its long-term strategy and for general corporate purposes, including the  funding of new growth opportunities in the Unmanned  Systems and Satellite Communications, Technology and Training  businesses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248143\" data-linked=\"Kratos Defense to launch 10.35M-share offering\" data-tweet=\"$KTOS - Kratos Defense to launch 10.35M-share offering https://seekingalpha.com/news/3248143-kratos-defense-to-launch-10_35m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3248143-kratos-defense-to-launch-10_35m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248139\" data-ts=\"1488463674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLNT\" target=\"_blank\">PLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248139-planet-fitness-falls-flat-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Planet Fitness falls flat after earnings</a></h4><ul> <li>Planet Fitness (NYSE:<a href='https://seekingalpha.com/symbol/PLNT' title='Planet Fitness'>PLNT</a>) trades lower, despite some strong Q4 numbers which included a 10.6% jump in comparable sales.</li> <li>Investors appears to be reacting to the company's guidance for 2017 revenue of $405M to $415M vs. $411M consensus and 2017 EPS of $0.72-$0.75 vs. $0.75 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3247817-planet-fitness-reports-q4-results\" target=\"_blank\">Planet Fitness reports Q4 results</a> (March 1)</li> <li>PLNT <font color='red'>-5.08%</font> premarket to $20.74.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3248139\" data-linked=\"Planet Fitness falls flat after earnings\" data-tweet=\"$PLNT - Planet Fitness falls flat after earnings https://seekingalpha.com/news/3248139-planet-fitness-falls-flat-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3248139-planet-fitness-falls-flat-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248138\" data-ts=\"1488463649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248138-transocean-files-to-delay-form-10-k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean files to delay Form 10-K</a></h4><ul><li>Transocean (NYSE:<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a>) <font color='red'>-2.1%</font> premarket after it asks to <a href=\"https://www.sec.gov/Archives/edgar/data/1451505/000155837017001257/g20170301rig_form12b-25.htm\" target=\"_blank\">delay filing its Form 10-K</a> for FY 2016, saying it needs additional time.</li><li>RIG cites its evaluation of disclosure controls  and procedures, and says it expects to disclose a material weakness in its internal control  over financial reporting in its Form 10-K related to its controls over  income tax accounting.</li><li>RIG says it has not completed its determination of related income tax expense and other  items, so adjustments may be required to the net income reported in its <a href=\"https://seekingalpha.com/news/3245620-transocean-beats-revenue\" target=\"_blank\">Q4 earnings</a> release.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248138\" data-linked=\"Transocean files to delay Form 10-K\" data-tweet=\"$RIG - Transocean files to delay Form 10-K https://seekingalpha.com/news/3248138-transocean-files-to-delay-form-10-k?source=tweet\" data-url=\"https://seekingalpha.com/news/3248138-transocean-files-to-delay-form-10-k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248133\" data-ts=\"1488463287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNST\" target=\"_blank\">MNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248133-monster-beverage-approves-new-500m-buyback-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monster Beverage approves new $500M buyback plan</a></h4><ul> <li>Monster Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a>) says its board <a href=\"https://seekingalpha.com/pr/16758593-monster-beverage-reports-2016-fourth-quarter-full-year-financial-results\" target=\"_blank\">approved</a> a new $500M share repurchase program after the company's old authorization was tapped out.</li> <li>Shares of Monster are up <font color='green'>13.43%</font> premarket to $47.65.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3247826-monster-beverage-beats-0_05-beats-revenue\" target=\"_blank\">Monster Beverage beats by $0.05, beats on revenue</a> (March 1)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248092-strong-earnings-send-monster-beverage-higher\" target=\"_blank\">Strong earnings send Monster Beverage higher</a> (March 2)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3248133\" data-linked=\"Monster Beverage approves new $500M buyback plan\" data-tweet=\"$MNST - Monster Beverage approves new $500M buyback plan https://seekingalpha.com/news/3248133-monster-beverage-approves-new-500m-buyback-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3248133-monster-beverage-approves-new-500m-buyback-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248130\" data-ts=\"1488463077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248130-juno-stops-development-of-jcar015-in-all-shares-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno stops development of JCAR015 in ALL; shares down 8% premarket</a></h4><ul><li>It is official. Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) <a href=\"https://seekingalpha.com/pr/16758579-juno-therapeutics-reports-fourth-quarter-2016-financial-results\" target=\"_blank\">announces </a>that has terminated development of former lead product candidate JCAR015 in treatment-resistant acute lymphoblastic leukemia &#40;ALL&#41; due to safety concerns. Several months ago, it stopped a mid-stage study after two patients suffered cerebral edema &#40;CE&#41;. One died and the other was not expected to recover. A total of five patients have died due to CE.</li><li>Shares are down&nbsp;<font color='red'>8%</font>&nbsp;premarket on average volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3226655-juno-slammed-suspension-mid-stage-study-lead-product-candidate-jcar015-shares-28-percent\" target=\"_blank\">Juno slammed on suspension of mid-stage study of lead product candidate JCAR015; shares down 28% premarket</a> (Nov. 23, 2016)</li><li><strong>Update</strong>: Juno's claw-back from its early-session sell-off appears to have failed. Shares are down<font color='red'> 11%</font>&nbsp;10 minutes before the close.</li></ul><div class=\"tiny-share-widget\" data-id=\"3248130\" data-linked=\"Juno stops development of JCAR015 in ALL; shares down 8% premarket\" data-tweet=\"$JUNO - Juno stops development of JCAR015 in ALL; shares down 8% premarket https://seekingalpha.com/news/3248130-juno-stops-development-of-jcar015-in-all-shares-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3248130-juno-stops-development-of-jcar015-in-all-shares-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3248126\" data-ts=\"1488462845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3248126-barnes-noble-cant-shake-off-sluggish-sales-trend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble can&#39;t shake off sluggish sales trend</a></h4><ul>     <li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) reports same-store sales fell 8.3% in <a href=\"https://seekingalpha.com/pr/16759443-barnes-and-noble-reports-fiscal-2017-third-quarter-financial-results\" target=\"_blank\">FQ3</a> on a soft traffic trend vs. -2% expected. The retailer ran into a tough comparable from last year when an Adele album stoked sales.</li>     <li>EBITDA cam in at $158M vs. $169M a year ago. Nook EBITDA was -$2.4M vs. -$11.2M last year.</li>     <li>Looking ahead, the company expects FY17 same-store sales to fall 7% and EBITDA to fall in a range of $180M to $190M.</li>     <li>BKS <font color='red'>-3.03%</font> premarket to $9.60 vs. a 52-week trading range of $9.40 to $13.63.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3248126\" data-linked=\"Barnes &amp; Noble can&#39;t shake off sluggish sales trend\" data-tweet=\"$BKS - Barnes &amp; Noble can&#39;t shake off sluggish sales trend https://seekingalpha.com/news/3248126-barnes-noble-cant-shake-off-sluggish-sales-trend?source=tweet\" data-url=\"https://seekingalpha.com/news/3248126-barnes-noble-cant-shake-off-sluggish-sales-trend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}